ACTIVE STUDIES RECRUITING:

• J3L-MC-EZEF (ACCLAIM-Lp(a)) – Cardiovascular risk/ lipoprotein(a) – Lp(a)

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin). The study’s duration will last up to 5 years.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

ACTIVE STUDIES NON-RECRUITING:

• EX6018-4758 (ZEUS) – Cardiovascular risk/CKD/Inflammation

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation. The study’s duration will last up to 4 years.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

• J2A-MC- GZGS – T2DM/Overweight/Obesity

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.

Those meeting the eligibility criteria will receive trial-related procedures and the study medication without incurring any costs. Additionally, participants may be compensated for their time and travel. If deemed eligible, attendance of routine visits based on a specific schedule will be required.

COMPLETED STUDIES:

  • AbbVie – M16-100 (TRAVERSE) – Hypogonadism/CVD – 2023

  • Amarin Pharma Inc. – AMR-01-01-0019 (REDUCE-IT) – cardiovascular disease – 2018

  • AstraZeneca – D5881C00004 (STRENGTH) – Cardiovascular Risk -2020

  • Novo Nordisk – NN6435-4697 – Atherosclerotic Cardiovascular Disease – 2022

info@PlanItResearch.com